AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Vedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease Week

May 20, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 20, 2019--

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced the presentation of expanded, long-term positive data from its Phase 1a/1b study of VE303, the Company’s lead, orally-administered live biotherapeutic product (LBP) candidate for recurrent Clostridium difficile infection (rCDI). The data were presented at Digestive Disease Week 2019, held in San Diego, California, and supports the dosing employed in the ongoing Phase 2 study of VE303 and further illuminate interactions between VE303 and gut microbiota.

The expanded data build on the preliminary results of the Phase 1a/1b study previously disclosed by the Company, which found that all doses of VE303 were safe and well-tolerated and that treatment with VE303 resulted in rapid, durable, and dose-dependent colonization of VE303 strains across a heterogenous group of 23 adults. The study also found that VE303 treatment accelerated the restoration of gut microbiota after a course of antibiotics.

“This study served as an important validation for our approach of developing rationally-defined consortia and our ability to quantify their pharmacology,” said Bernat Olle, Ph.D., chief executive officer of Vedanta Biosciences. “These expanded data underscore the benign safety profile of VE303 and further demonstrate the pharmacokinetics of colonization and its relationship to dose exposure and gut microbiota restoration after treatment with antibiotics.”

In late 2018, Vedanta announced the initiation of a Phase 2, multi-center, randomized, double-blind, placebo-controlled study (“CONSORTIUM”) designed to evaluate the safety and efficacy of two doses of VE303 compared to placebo in patients with rCDI. The study is expected to enroll up to 146 patients with a recent diagnosis of rCDI, confirmed using a Clostridium difficile toxin assay, and who have completed a course of antibiotics but remain at risk for recurrence. The primary endpoint will be prevention of infection recurrence at eight weeks.

About VE303
VE303 is a first-in-class orally-administered investigational live biotherapeutic product (LBP) consisting of a defined bacterial consortium. It is produced under GMP conditions from pure, clonal bacterial cell banks, which yield a standardized drug product in powdered form and bypasses the need to rely on direct sourcing of fecal donor material of inconsistent composition. VE303 is designed to restore colonization resistance against gut pathogens, including C.  difficile, after treatment with antibiotics. In 2017, Vedanta Biosciences received a $5.4 million research grant from CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) to support clinical studies of VE303. VE303 was granted Orphan Drug Designation in 2017 by the United States Food and Drug Administration (FDA) for the prevention of recurrent C . difficile  infection (rCDI) and is currently being evaluated in a Phase 2 clinical study for the treatment of rCDI.

About Vedanta Biosciences
Vedanta Biosciences  is a clinical-stage microbiome leader developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. Vedanta’s proprietary capabilities include what is believed to be the largest collection of human-gut associated bacteria, assays and bioinformatics techniques for consortia design and optimization, vast datasets from human interventional studies and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form.

Vedanta Biosciences’ pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. These advances have been published in leading peer-reviewed journals, including Science ( multiple ), Nature ( 2013,2019 ), Cell, and Nature Immunology. Vedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of investigational live biotherapeutic products (LBPs) in infectious disease, autoimmune disease, allergy, and immuno-oncology. This pipeline includes 2 clinical-stage product candidates currently being evaluated for the treatment of recurrent C . difficile  infection and inflammatory bowel disease (in collaboration with Janssen Biotech, Inc.) as well as two additional product candidates entering the clinic in 2019 in food allergy and in patients with advanced or metastatic cancers (in combination with Bristol-Myers Squibb’s checkpoint inhibitor OPDIVO ® ).

Vedanta’s IP portfolio contains 20 US patents and numerous foreign issuances with coverage extending to 2037. Earlier this year, the European Patent Office upheld Vedanta’s foundational Honda Patent, which is now issued in major commercial markets, including the United States, Europe, and Japan. Vedanta Biosciences was founded by PureTech Health (LSE.PRTC). Its scientific co-founders are world-renowned experts in immunology and microbiology who have pioneered the fields of innate immunity, Th17 and regulatory T cell biology.

Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190520005455/en/

CONTACT: Investors

Allison Mead Talbot

+1 617 651 3156

amt@puretechhealth.com

US media

Tom Donovan

+1 857 559 3397

tom@tenbridgecommunications.com

KEYWORD: UNITED KINGDOM UNITED STATES EUROPE NORTH AMERICA CALIFORNIA MASSACHUSETTS IRELAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Vedanta Biosciences

Copyright Business Wire 2019.

PUB: 05/20/2019 12:30 PM/DISC: 05/20/2019 12:30 PM

http://www.businesswire.com/news/home/20190520005455/en

All contents © copyright 2019 The Associated Press. All rights reserved.